Anbio Biotechnology Limited (NNNN)
Market Closed
17 Jul, 20:00
$
9. 49
-0.11
-1.1458%
$
412.14M Market Cap
- P/E Ratio
- Div Yield
51,700 Volume
- Eps
$ 9.6
Previous Close Investors:
Want to track NNNN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Anbio Biotechnology's Hype And Hard Approvals Suggest A Stretched Valuation
Anbio Biotechnology is a medical device firm specializing in in-vitro diagnostics, with recent stock volatility and a thin public float. I believe they continue to face significant regulatory hurdles in both the EU (IVDR transition) and the US (FDA clearance). Likewise, NNNN trades at an extremely high valuation relative to its fundamentals and peers.
Seekingalpha | 9 months ago
Anbio Biotechnology Pursues U.S. IPO For Its IVD Products Launch
Anbio Biotechnology plans to raise $8.8 million in an IPO to commercialize its in vitro diagnostics products amid market risks. The company has experienced fluctuating revenue and profitability, with significant customer concentration risks. The global IVD market is projected to grow to $119 billion by 2030, but Anbio faces stiff competition from well-established industry players.
Seekingalpha | 1 year ago
